Professor | Xuejing Shao | Asia Growth Partners

	Upload Avatar (500 x 500)
Name	Xuejing Shao
Contact Information	xjshao@zju.edu.cn
Language ability	Chinese, English
Province	Zhejiang

Upload Avatar (500 x 500)

Name

Xuejing Shao

Contact Information

xjshao@zju.edu.cn

Language ability

Chinese, English

Province

Zhejiang

University/Lab Affiliation and Title	Zhejiang University
Faculty	Pharmaceutical Sciences
Academic Background & Achievements	2022 - Present: Distinguished Researcher, Zhejiang University 2017 - 2021: Postdoctoral Researcher, Zhejiang University, Supervisor: Professor Bo Yang 2012 - 2017: Ph.D. in Pharmacology, Zhejiang University, Supervisor: Professor Qiaojun He 2008 - 2012: Bachelor of Science, Zhejiang University Hosted 8 research projects including National Natural Science Foundation projects Published 15 SCI papers in journals like Blood, Leukemia, Cell Death Differ, Nat Chem Biol Granted 6 national invention patents
Work Experience	2022 - Present: Zhejiang University - Distinguished Researcher 2017 - 2021: Zhejiang University - Postdoctoral Researcher 2012 - 2017: Zhejiang University - Ph.D. Student 2008 - 2012: Zhejiang University - Bachelor Student
Awards	Second Prize of Zhejiang Pharmaceutical Association Science and Technology Award Selected for Zhejiang Association for Science and Technology Youth Talent Support Project

University/Lab Affiliation and Title

Zhejiang University

Faculty

Pharmaceutical Sciences

Academic Background & Achievements

2022 - Present: Distinguished Researcher, Zhejiang University
2017 - 2021: Postdoctoral Researcher, Zhejiang University, Supervisor: Professor Bo Yang
2012 - 2017: Ph.D. in Pharmacology, Zhejiang University, Supervisor: Professor Qiaojun He
2008 - 2012: Bachelor of Science, Zhejiang University
Hosted 8 research projects including National Natural Science Foundation projects
Published 15 SCI papers in journals like Blood, Leukemia, Cell Death Differ, Nat Chem Biol
Granted 6 national invention patents

Work Experience

2022 - Present: Zhejiang University - Distinguished Researcher
2017 - 2021: Zhejiang University - Postdoctoral Researcher
2012 - 2017: Zhejiang University - Ph.D. Student
2008 - 2012: Zhejiang University - Bachelor Student

Awards

Second Prize of Zhejiang Pharmaceutical Association Science and Technology Award
Selected for Zhejiang Association for Science and Technology Youth Talent Support Project

Areas of Focus	Tumor Pharmacology New Targets and Strategies for Anti-Leukemia Drugs Based on Fusion Proteins Innovative Anti-Tumor Drugs Based on Tumor Cell Differentiation
Publications	Palmitoyltransferase ZDHHC21 regulates oxidative phosphorylation to induce differentiation block and stemness in AML, Shao XJ#, Xu AX#, Du WX, Xu T, Huang YP, Xia ZM, Wang W, Cai MY, Zhang XY, Zhang JH, Cao J, Xu XJ, Yang B, He QJ, Ying MD, 2023 A novel gene fusion RUNX1/ZNF423 promotes leukemic relapse of NUP98-rearranged AML, Du WX, Xia ZM, Luo ZB, Chen YC, Bing SW, Wang W, Zhang XY, Zhou Z, Zhang JY, Cao J, Yang B, He QJ, Shao XJ, Xu XX, Ying MD, 2023 Deneddylation of PML/RARa Reconstructs Functional PML Nuclear Bodies via Orchestrating Phase Separation to Eradicate APL, Shao XJ#, Chen YQ#, Xu AX#, Xiang DY, Wang W, Du WX, Huang YP, Zhang XY, Cai MY, Xia ZM, Wang Y, Cao J, Zhang Y, Yang B, He QJ, Ying MD, 2022 Blockade of deubiquitinase YOD1 degrades oncogenic PML/RARa and eradicates acute promyelocytic leukemia cells, Shao XJ#, Chen YQ#, Wang W, Du WX, Zhang XY, Cai MY, Bing SW, Cao J, Xu XJ, Yang B, He QJ, Ying MD, 2022 CDK2 suppression synergizes with all-trans-retinoic acid to overcome the myeloid differentiation blockade of AML cells, Shao XJ, Xiang SF, Fu HR, Chen YQ, Xu AX, Liu YJ, Qi XT, Cao J, Zhu H, Yang B, He QJ, Ying MD, 2020 Targeting Cul3-scaffold E3 ligase complex via KLHL substrate adaptors for cancer therapy, Xiang SF, Shi XX, Chen PF, Chen YF, Bing SW, Jin XZ, Cao J, Wang JH, Yang B, Shao XJ, He QJ, Ying MD, 2021 Discovery of a first-in-class CDK2 selective degrader for AML differentiation therapy, Wang LG#, Shao XJ#, Zhong TB#, Wu Y#, Xu AX#, Sun XY, Gao HY, Liu YB, Lan TL, Tong Y, Tao X, Du WX, Wang W, Chen YQ, Li T, Meng XB, Deng HT, Yang B, He QJ, Ying MD, Rao Y, 2021 Inhibition of M2-like Macrophages by All-Trans Retinoic Acid Prevents Cancer Initiation and Stemness in Osteosarcoma Cells, Shao XJ, Xiang SF, Chen YQ, Zhang N, Cao J, Zhu H, Yang B, Zhou Q, Ying MD, He QJ, 2019 2-Bromopalmitate sensitizes osteosarcoma cells to adriamycin-induced apoptosis via the modulation of CHOP, Xu T, Huang C, Qi XT, Yang XC, Zhang N, Cao J, Wang C, Zhu H, Yang B, He QJ, Shao XJ, Ying MD, 2019 Driving the Degradation of Oncofusion Proteins for Targeted Cancer Therapy, Zhang XY, Chen YQ, Yang B, Shao XJ, Ying MD, 2023 The Role of Autophagy in Targeted Therapy for Acute Myeloid Leukemia, Du WX, Xu AX, Huang YP, Cao J, Zhu H, Yang B, Shao XJ, He QJ, Ying MD, 2021 Protein Phase Separation: a novel therapy for cancer?, Wang W, Chen YQ, Xu AX, Cai MY, Cao J, Zhu H, Yang B, Shao XJ, Ying MD, He QJ, 2020 Advances in differentiation therapy for osteosarcoma, Chen YQ, Cao J, Zhang N, Yang B, He QJ, Shao XJ, Ying MD, 2020 Advances in targeted therapy for osteosarcoma based on molecular classification, Chen YQ, Liu RZ, Wang W, Wang C, Zhang N, Shao XJ, He QJ, Ying MD, 2021 Post-translational modification of retinoic acid receptor alpha and its roles in tumor cell differentiation, Xu AX, Zhang N, Cao J, Zhu H, Yang B, He Q, Shao XJ, Ying MD, 2020

Areas of Focus

Tumor Pharmacology
New Targets and Strategies for Anti-Leukemia Drugs Based on Fusion Proteins
Innovative Anti-Tumor Drugs Based on Tumor Cell Differentiation

Publications

Palmitoyltransferase ZDHHC21 regulates oxidative phosphorylation to induce differentiation block and stemness in AML, Shao XJ#, Xu AX#, Du WX, Xu T, Huang YP, Xia ZM, Wang W, Cai MY, Zhang XY, Zhang JH, Cao J, Xu XJ, Yang B, He QJ, Ying MD*, 2023
A novel gene fusion RUNX1/ZNF423 promotes leukemic relapse of NUP98-rearranged AML, Du WX, Xia ZM, Luo ZB, Chen YC, Bing SW, Wang W, Zhang XY, Zhou Z, Zhang JY, Cao J, Yang B, He QJ, Shao XJ*, Xu XX*, Ying MD*, 2023
Deneddylation of PML/RARa Reconstructs Functional PML Nuclear Bodies via Orchestrating Phase Separation to Eradicate APL, Shao XJ#, Chen YQ#, Xu AX#, Xiang DY, Wang W, Du WX, Huang YP, Zhang XY, Cai MY, Xia ZM, Wang Y, Cao J, Zhang Y, Yang B, He QJ, Ying MD*, 2022
Blockade of deubiquitinase YOD1 degrades oncogenic PML/RARa and eradicates acute promyelocytic leukemia cells, Shao XJ#, Chen YQ#, Wang W, Du WX, Zhang XY, Cai MY, Bing SW, Cao J, Xu XJ, Yang B, He QJ, Ying MD*, 2022
CDK2 suppression synergizes with all-trans-retinoic acid to overcome the myeloid differentiation blockade of AML cells, Shao XJ, Xiang SF, Fu HR, Chen YQ, Xu AX, Liu YJ, Qi XT, Cao J, Zhu H, Yang B, He QJ, Ying MD*, 2020
Targeting Cul3-scaffold E3 ligase complex via KLHL substrate adaptors for cancer therapy, Xiang SF, Shi XX, Chen PF, Chen YF, Bing SW, Jin XZ, Cao J, Wang JH, Yang B, Shao XJ*, He QJ*, Ying MD*, 2021
Discovery of a first-in-class CDK2 selective degrader for AML differentiation therapy, Wang LG#, Shao XJ#, Zhong TB#, Wu Y#, Xu AX#, Sun XY, Gao HY, Liu YB, Lan TL, Tong Y, Tao X, Du WX, Wang W, Chen YQ, Li T, Meng XB, Deng HT, Yang B, He QJ, Ying MD*, Rao Y*, 2021
Inhibition of M2-like Macrophages by All-Trans Retinoic Acid Prevents Cancer Initiation and Stemness in Osteosarcoma Cells, Shao XJ, Xiang SF, Chen YQ, Zhang N, Cao J, Zhu H, Yang B, Zhou Q*, Ying MD*, He QJ*, 2019
2-Bromopalmitate sensitizes osteosarcoma cells to adriamycin-induced apoptosis via the modulation of CHOP, Xu T, Huang C, Qi XT, Yang XC, Zhang N, Cao J, Wang C, Zhu H, Yang B, He QJ, Shao XJ*, Ying MD*, 2019
Driving the Degradation of Oncofusion Proteins for Targeted Cancer Therapy, Zhang XY, Chen YQ, Yang B, Shao XJ*, Ying MD*, 2023
The Role of Autophagy in Targeted Therapy for Acute Myeloid Leukemia, Du WX, Xu AX, Huang YP, Cao J, Zhu H, Yang B, Shao XJ*, He QJ*, Ying MD*, 2021
Protein Phase Separation: a novel therapy for cancer?, Wang W, Chen YQ, Xu AX, Cai MY, Cao J, Zhu H, Yang B, Shao XJ*, Ying MD*, He QJ*, 2020
Advances in differentiation therapy for osteosarcoma, Chen YQ, Cao J, Zhang N, Yang B, He QJ, Shao XJ*, Ying MD*, 2020
Advances in targeted therapy for osteosarcoma based on molecular classification, Chen YQ, Liu RZ, Wang W, Wang C, Zhang N, Shao XJ*, He QJ*, Ying MD*, 2021
Post-translational modification of retinoic acid receptor alpha and its roles in tumor cell differentiation, Xu AX, Zhang N, Cao J, Zhu H, Yang B, He Q, Shao XJ*, Ying MD*, 2020

Cancer Pharmacology Leukemia Fusion Proteins Drug Targets Tumor Cell Differentiation Innovative Drugs Therapeutic Strategies Post-Translational Modifications Small Molecule Drugs

Hongrui Liu - Fudan University

Wenfu Tan - Fudan University

Ke Yu - Fudan University

View All

Personal Information

Academic Information

Research

Contact us

No account yet?

Personal Information

Academic Information

Research

Contact us